[Digestive cancers and choroid metastasis. Diagnostic circumstances and prognostic value apropos of 2 cases]

J P Cailliez-Tomasi¹, C Avisse, O Bouché

¹Service de Chirurgie Générale et Digestive, C.H.U. Reims.

|October 17, 1998

Abstract:

We report two observations of malignant gastric and pancreatic tumors with choroid metastasis. Clinical course was rapidly and spontaneously unfavorable.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis.

ESMO open·2026

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

medRxiv : the preprint server for health sciences·2026

Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study).

ESMO gastrointestinal oncology·2026

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.

ESMO open·2025

See all related articles

Related Experiment Videos

[Digestive cancers and choroid metastasis. Diagnostic circumstances and prognostic value apropos of 2 cases]

Related Concept Videos

Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis.

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study).

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.

Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.

[Not Available].

[Not Available].

[Not Available].

[Not Available].

[Not Available].

[Not Available].

Related Experiment Videos

[Digestive cancers and choroid metastasis. Diagnostic circumstances and prognostic value apropos of 2 cases]

Abstract:

Related Concept Videos

Related Articles